PMID- 30123344
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230928
IS  - 1837-9664 (Print)
IS  - 1837-9664 (Electronic)
IS  - 1837-9664 (Linking)
VI  - 9
IP  - 16
DP  - 2018
TI  - The Efficacy and Safety of Apatinib Treatment for Patients with Unresectable or 
      Relapsed Liver Cancer: a retrospective study.
PG  - 2773-2777
LID - 10.7150/jca.26376 [doi]
AB  - Purpose: Liver cancer is insensitive to chemotherapy. Sorafenib is currently the 
      standard treatment for patients with advanced diseases, with mild survival 
      extension and several intolerable drug-related side effects. The establishment of 
      new treatments is an unmet clinical need. The aim of our study was to assess the 
      efficacy and safety of apatinib, a novel antiangiogenic drug, in the treatment of 
      patients with liver cancer. Materials and Methods: Patients with unresectable or 
      relapsed liver cancer were included in a single center, retrospective, 
      observational study and treated with apatinib until progressive disease or 
      unacceptable toxicity. Results: 32 patients were reviewed from January 2015 to 
      March 2017. No complete response (CR) occurred, 5 patients (16%) showed partial 
      response (PR), 14 patients (44%) had stable disease (SD), 13 patients (41%) had 
      progressive disease (PD), with disease control rate of 60%. Median 
      progression-free survival (PFS) was 5 months (95% confidence interval [CI]: 
      4.3-6.1 months) for hepatocellular carcinoma (HCC) and 3 months (95% CI: 2.5-4.2 
      months) for intrahepatic cholangiocarcinoma (ICC). The median overall survival 
      (OS) was 13 months (95% CI: 12.4-14.1 months) for HCC and 5 months (95% CI: 
      4.5-6.2 months) for ICC, respectively. The most common adverse effects (AEs) were 
      proteinuria (31%), secondary hypertension (28%) and liver dysfunction (13%). 
      Conclusion: Apatinib treatment was an effective for patients with liver cancer. 
      The toxicities were mild and tolerable.
FAU - Zhen, Liu
AU  - Zhen L
AD  - Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, Zhejiang, China.
FAU - Jiali, Chen
AU  - Jiali C
AD  - Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, Zhejiang, China.
FAU - Yong, Fang
AU  - Yong F
AD  - Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, Zhejiang, China.
FAU - Han, Xufeng
AU  - Han X
AD  - Department of Internal Medicine, Yuyao Traditional Chinese Medicine Hospital, 
      Yuyao, Zhejiang, China.
FAU - Hongming, Pan
AU  - Hongming P
AD  - Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, Zhejiang, China.
FAU - Weidong, Han
AU  - Weidong H
AD  - Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, Zhejiang, China.
LA  - eng
PT  - Journal Article
DEP - 20180716
PL  - Australia
TA  - J Cancer
JT  - Journal of Cancer
JID - 101535920
PMC - PMC6096375
OTO - NOTNLM
OT  - Liver cancer
OT  - angiogenesis
OT  - apatinib
OT  - retrospective study
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2018/08/21 06:00
MHDA- 2018/08/21 06:01
PMCR- 2018/01/01
CRDT- 2018/08/21 06:00
PHST- 2018/03/29 00:00 [received]
PHST- 2018/05/08 00:00 [accepted]
PHST- 2018/08/21 06:00 [entrez]
PHST- 2018/08/21 06:00 [pubmed]
PHST- 2018/08/21 06:01 [medline]
PHST- 2018/01/01 00:00 [pmc-release]
AID - jcav09p2773 [pii]
AID - 10.7150/jca.26376 [doi]
PST - epublish
SO  - J Cancer. 2018 Jul 16;9(16):2773-2777. doi: 10.7150/jca.26376. eCollection 2018.